Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | USP28 | Q96RU2 | 2/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | BRD2 | P25440 | 1/20 | 0.39 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.39 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1599834 | 0.83 | USP28 (0.39) | PTGDR2NPC1RAB9AMAPK1HSD17B10 | |
| SCHEMBL20465747 | 0.82 | PYCR1 (0.46) | PTGDR2NPC1RAB9AMAPK1HSD17B10 | |
| SCHEMBL507839 | 0.82 | PYCR1 (0.46) | PTGDR2NPC1RAB9AMAPK1HSD17B10 | |
| SCHEMBL1487566 | 0.79 | CA2 (0.42) | PTGDR2NPC1RAB9AUSP28DPP4 | |
| SCHEMBL138081 | 0.79 | DPP4 (0.41) | NPC1RAB9AUSP28DPP4DGAT1 | |
| SCHEMBL29137937 | 0.79 | DPP4 (0.41) | NPC1RAB9AUSP28DPP4DGAT1 | |
| SCHEMBL795719 | 0.78 | PTGDR2 (0.48) | PTGDR2NPC1RAB9AMAPK1HSD17B10 | |
| SCHEMBL29417721 | 0.78 | PTGDR2 (0.48) | PTGDR2NPC1RAB9AMAPK1HSD17B10 | |
| SCHEMBL1106603 | 0.77 | CCR5 (0.45) | DPP4DGAT1BRD4BRD2BRD3 | |
| SCHEMBL20560539 | 0.77 | DPP4 (0.40) | NPC1RAB9AUSP28DPP4DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 201 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595273-B2 | Phosphonate conjugates and uses thereof | TRANSLATIONAL GENOMICS RES INST (US) | 2026-04-07 | — | — | US | disclosed |
| US-20250214942-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-07-03 | — | — | US | disclosed |
| US-12286406-B2 | Inhibitors of receptor interacting protein kinase I for the treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-04-29 | — | — | US | disclosed |
| US-20250115597-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO LTD (CN) | 2025-04-10 | — | — | US | disclosed |
| US-12129250-B2 | TYK2 inhibitors and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-10-29 | — | — | US | disclosed |
| EP-4448514-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | Lynk Pharmaceuticals Co. Ltd. (CN) | 2024-10-23 | — | — | EP | disclosed |
| CN-115605463-B | Inhibitors of receptor-interacting protein kinase I for the treatment of diseases | 德州大学系统董事会 | 2024-08-09 | — | — | CN | disclosed |
| CN-118401516-A | TYK2 inhibitors, compositions and methods thereof | 凌科药业(杭州)有限公司 | 2024-07-26 | — | — | CN | disclosed |
| US-20240199554-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2024-06-20 | — | — | US | disclosed |
| US-20240124448-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-04-18 | — | — | US | disclosed |
| WO-1998024784-A1 | SUBSTITUTED SULFONIC ACID N-[(AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLAMIDE COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-06-11 | — | — | WO | disclosed |
| US-5731315-A | Substituted sulfonic acid n- (aminoiminomethyl)phenylalkyl!-azaheterocyclamide compounds | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-03-24 | — | — | US | disclosed |
| CN-1173867-A | Indolyl neuropeptide Y receptor antagonists | LILLY CO ELI (US) | 1998-02-18 | — | — | CN | disclosed |
| EP-0789688-A4 | INDOLYL NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 1997-11-19 | — | — | EP | disclosed |
| EP-0789688-A1 | INDOLYL NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1997-08-20 | — | — | EP | disclosed |
| WO-1997009308-A1 | INDOLYL NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1997-03-13 | — | — | WO | disclosed |
| EP-0232997-B1 | ANTIHYPERCHOLESTEROLEMIC COMPOUNDS | MERCK & CO. INC. (US) | 1990-09-19 | — | — | EP | disclosed |
| US-4855321-A | Antihypercholesterolemic compounds | MERCK & CO., INC. (US) | 1989-08-08 | — | — | US | disclosed |
| US-4772626-A | ENZYME INHIBITORS, ANTILIPEMIC AGENTS, TETRAHYDRO-HYDROXYPYRANONES | MERCK & CO., INC. (US) | 1988-09-20 | — | — | US | disclosed |
| EP-0232997-A1 | Antihypercholesterolemic compounds | MERCK & CO. INC. (US) | 1987-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214942-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | RIPK1, RIPK2, RIPK4 | PTGDR2 2900/4885NPC1 1506/4885RAB9A 1248/4885 |
| US-12286406-B2 | Inhibitors of receptor interacting protein kinase I for the treatment of disease | RIPK1, RIPK2, RIPK4 | PTGDR2 2900/4885NPC1 1506/4885RAB9A 1248/4885 |
| US-20240124448-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | TYK2, JAK2, JAK1 | PTGDR2 3987/4885NPC1 4269/4885RAB9A 2745/4885 |
| US-20250115597-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | TYK2, JAK2, JAK1 | PTGDR2 3987/4885NPC1 4269/4885RAB9A 2745/4885 |
| US-12129250-B2 | TYK2 inhibitors and compositions and methods thereof | TYK2, JAK2, JAK1 | PTGDR2 3987/4885NPC1 4269/4885RAB9A 2745/4885 |
| US-12595273-B2 | Phosphonate conjugates and uses thereof | RET, PTK2, ERBB2 | PTGDR2 771/4885NPC1 1698/4885RAB9A 612/4885 |
| US-20240199554-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | RIPK1, RIPK2, RIPK4 | PTGDR2 2900/4885NPC1 1506/4885RAB9A 1248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.